When did NGM BIOPHARMACEUTICALS INC (NGM) report earnings last quarter?
NGM BIOPHARMACEUTICALS INC (NGM) last reported earnings on 3/11/2024.
NASDAQ:NGM • US62921N1054
Past quarterly earnings results for NGM BIOPHARMACEUTICALS INC (NGM), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2023 | -0.33 | -0.40 | 16.90% | 26.67% | 165K | 563.782K | -70.73% | -99.09% |
| Q3 2023 | -0.35 | -0.43 | 18.33% | 40.68% | 580K | 2.48M | -76.61% | -92.67% |
| Q2 2023 | -0.46 | -0.50 | 8.51% | 22.03% | 1.42M | 3.337M | -57.45% | -82.87% |
| Q1 2023 | -0.58 | -0.52 | -11.04% | -38.10% | 2.25M | 6.198M | -63.70% | -89.26% |
| Q4 2022 | -0.45 | -0.52 | 13.49% | -28.57% | 18.18M | 6.831M | 166.14% | -13.26% |
| Q3 2022 | -0.59 | -0.60 | 1.27% | -59.46% | 7.91M | 7.135M | 10.86% | -57.43% |
| Q2 2022 | -0.59 | -0.56 | -6.21% | -22.92% | 8.29M | 13.533M | -38.74% | -50.57% |
| Q1 2022 | -0.42 | -0.46 | 9.20% | -16.67% | 20.95M | 18.868M | 11.03% | -2.92% |
| Q4 2021 | -0.35 | -0.36 | 3.74% | 12.50% | 20.96M | 20.398M | 2.76% | 6.02% |
| Q3 2021 | -0.37 | -0.35 | -4.67% | 13.95% | 18.58M | 22.879M | -18.79% | -20.87% |
| Q2 2021 | -0.48 | -0.38 | -27.87% | -26.32% | 16.77M | 22.708M | -26.15% | -15.13% |
| Q1 2021 | -0.36 | -0.42 | 14.88% | -28.57% | 21.58M | 22.717M | -5.01% | -11.41% |
| Q4 2020 | -0.40 | -0.48 | 15.93% | - | 19.77M | 22.186M | -10.89% | - |
| Q3 2020 | -0.43 | -0.38 | -12.43% | - | 23.48M | 20.019M | 17.29% | - |
| Q2 2020 | -0.38 | -0.32 | -20.20% | - | 19.76M | 21.996M | -10.17% | - |
| Q1 2020 | -0.28 | -0.27 | -3.64% | - | 24.36M | 23.18M | 5.09% | - |
Notes
NGM BIOPHARMACEUTICALS INC (NGM) last reported earnings on 3/11/2024.
NGM BIOPHARMACEUTICALS INC (NGM) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, NGM BIOPHARMACEUTICALS INC (NGM) has beaten EPS estimates in 3 out of 4 releases.